Graft failure is one of the major life-threatening complications after allogeneic hematopoietic stem cell transplantation (allo-SCT). HLA-mismatched SCT is associated with high incidence of GVHD and graft failure. 1, 2 Recently, HLA-haploidentical SCT (haploSCT) using post-transplant cyclophosphamide (PTCy-haploSCT) has been increasingly performed. 3, 4 It has been suggested that hematopoietic progenitors are resistant to cyclophosphamide due to high expression of aldehyde dehydrogenase, which convert cyclophosphamide to the inactive metabolites, 5 and the rate of graft failure is acceptable with around 5% after PTCy-haploSCT. [6] [7] [8] [9] [10] PTCy-haploSCT could be readily performed as the second or salvage SCT in relapsed or rejected patients after allo-SCT who lack an HLA-compatible related or unrelated donors. 10, 11 However, risks of graft failure after repetitive allo-SCT are not well documented and it remains to be investigated weather a history of prior allo-SCT could be a risk factor for graft rejection. We conducted a prospective multicenter phase II study (JSCT-Haplo13: UMIN-CTR UMIN000010316) of post-transplant cyclophosphamide-based HLA-haploidentical PBSC transplantation (PBSCT). 10 Written informed consents were obtained from patients in accordance with the Declaration of Helsinki. In this report, we discuss risks of graft failure in patients with a history of prior allo-SCT.
JSCT-Haplo13 study included 31 patients with hematologic malignancies. Details of patients characteristics and transplant procedures were reported previously. 10 There were no patients with aplastic anemia. Positivity for donor-specific antibodies (DSA) was one of the exclusion criteria of JSCT-Haplo13 study. DSA were checked before PTCy-haploSCT once, and all the patients were negative for DSA in this study. Graft failure was defined as alive on day 28 with absolute neutrophil counto0.5 × 10 9 /L and 1 patient who died by day 28 after SCT were excluded in the current analysis.
Eighteen patients had no history of prior allo-SCT, whereas 12 patients had a history of prior SCT; 5 and 7 patients had received HLA-matched SCT and HLA-mismatched SCT (Table 1 ). There were no differences in disease status, CD34
+ cell dose and numbers of HLA mismatches between the current donor and the host between 18 patients without prior allo-SCT and the 12 patients with prior allo-SCT (data not shown). No graft failure occurred in 18 patients without a history of prior allo-SCT. In sharp contrast, graft failure developed in 3 out of 12 patients (25%) with a history of prior allo-SCT. In 12 patients who had a prior history of allo-SCT, again, there were no differences in disease status, CD34
+ cell dose and numbers of HLA mismatches between the current donor and host between nine patients who achieved engraftment and three patients who experienced rejection (data not shown). There was no specific association of the gender of recipient, first donor and second donor between rejected patients and engrafted patients (data not shown). There was no significant difference in T-cell doses in the graft between three rejected patients and 4 engrafted patients (data not shown).
Notably, graft failure occurred in three out of seven patients with a history of prior HLA-mismatched SCT, whereas all the patients with a history of HLA-matched SCT achieved engraftment (Table 1) . Donor chimerism was undetectable in bone marrow in two patients, while it was unable to evaluate in one patient due to low cellularity in bone marrow. In the repetitive HLA mismatched SCT, rejection is primarily mediated by host T cells derived from the previous donor. We carefully took a look at HLA disparities between patient, previous donor in the absence of DSA and current donor (Table 2 ). In six of the seven patients with a history of prior HLA-mismatched SCT, the current donor and patient shared HLA alleles that were mismatched for the previous donor (Table 2 , underlined), regardless of engraftment or rejection. All the patients who rejected had received bone marrow transplantation (BMT) or PBSCT, and two of the three developed acute and chronic GVHD. In these three patients, chimerism study using bone marrow mononuclear cells showed complete donor chimerism after prior SCT. Complete donor chimerism was confirmed in two patients before PTCy-haploSCT, while chimerism was not evaluated in one patient who were not in remission.
These results suggest that host-reactive memory T cells derived from the previous donor, which had recognized mismatched HLA expressed on the host and caused GVHD after the prior SCT, may be responsible for rejection of the second graft expressing the shared HLAs with the host. A recent study demonstrated that antigen-specific memory T cells were more resistant to high-dose Cy than naïve T cells. 12 In addition, reduced-intensity conditioning employed at the second SCT may not be sufficient to suppress host immune system. DSA is known to reappear after exposure to the antigens, but was again negative after rejection in one of the three patients evaluated.
Interestingly, all the patients who had undergone cord blood transplantation (CBT) did not develop chronic GVHD and achieved engraftment after PTCy-haploSCT. It has been well acknowledged that the incidence of chronic GVHD following single unit CBT is less than that after PBSCT or BMT. 13, 14 Thus, generation of anti-host memory T cells, which may be responsible for the rejection of the second donor graft, might not be less frequent after single unit CBT than after PBSCT/BMT. However, this should be evaluated in a larger cohort of patients.
In conclusion, our study uncovers previously unrecognized risks of graft rejection in a repetitive allo-SCT; a history of prior HLA-mismatched allogeneic PBSCT/BMT, where the current donor and host share HLA allele that are mismatched for the previous donor and targets of GVHD at the previous SCT, is a risk factor for graft rejection. HLA disparity between the previous and current donors and host should be taken into consideration and more immunosuppressive conditioning regimen might be required in such a situation to inhibit anti-host memory T cells. Abbreviations: GVHD = graft-versus-host disease; HLA = human leucocyte antigen. Bold and underlined: shared mismatched HLA alleles between patient and the 2nd donor, which were mismatched for the 1st donor.
